Is the combination of linagliptin and allopurinol better prophylaxis against post-contrast acute kidney injury? A multicenter prospective randomized controlled study

References

• Cho E, Ko GJ. The pathophysiology and the management of Radiocontrast-Induced nephropathy. Diagnostics. 2022;12(1):180.
   Web of Science ®Google Scholar
• Mehran R, Nikolsky E. Contrast-induced nephropathy: definition, epidemiology, and patients at risk. Kidney Int Suppl. 2006;100:S11–S15.
   Web of Science ®Google Scholar
• Pisani A, Riccio E, Andreucci M, et al. Role of reactive oxygen species in the pathogenesis of radiocontrast-induced nephropathy. Biomed Res Int. 2013;2013:1–6.
   Web of Science ®Google Scholar
• Bellos I, Iliopoulos DC, Perrea DN. Allopurinol administration for the prevention of Contrast-Induced nephropathy: a network meta-analysis with trial sequential analysis. J Cardiovasc Pharmacol. 2019;73(5):307–315.
   PubMed Web of Science ®Google Scholar
• Xin W, Lin Z, Zhang T, et al. Effects of allopurinol pretreatment on the risk of contrast-induced acute kidney injury in patients undergoing percutaneous coronary intervention: a meta-analysis of randomized controlled trials. CN. 2020;93(1):24–33.
   Google Scholar
• Chao CT, Wang J, Wu HY, et al. Dipeptidyl peptidase 4 inhibitor use is associated with a lower risk of incident acute kidney injury in patients with diabetes. Oncotarget. 2017;8(32):53028–53040. Published 2017 May 23.
   PubMedGoogle Scholar
• Cappetta D, Ciuffreda LP, Cozzolino A, et al. Dipeptidyl peptidase 4 inhibition ameliorates chronic kidney disease in a model of Salt-Dependent hypertension. Oxid Med Cell Longev. 2019;2019:1–13. Published 2019 Jan 10.
   Web of Science ®Google Scholar
• Mehran R, Aymong ED, Nikolsky E, et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol. 2004;44(7):1393–1399.
   PubMed Web of Science ®Google Scholar
• Barrett BJ, Parfrey PS. Clinical practice. Preventing nephropathy induced by contrast medium. N Engl J Med. 2006;354(4):379–386.
   PubMed Web of Science ®Google Scholar
• McCullough PA, Adam A, Becker CR, CIN Consensus Working Panel, et al. Risk prediction of contrast-induced nephropathy. Am J Cardiol. 2006;98(6A):27K–36K.
   PubMed Web of Science ®Google Scholar
• Tsai TT, Patel UD, Chang TI, et al. Contemporary incidence, predictors, and outcomes of acute kidney injury in patients undergoing percutaneous coronary interventions: insights from the NCDR Cath-PCI registry. JACC Cardiovasc Interv. 2014;7(1):1–9.
   PubMed Web of Science ®Google Scholar
• Rudnick MR, Goldfarb S, Wexler L, et al. Nephrotoxicity of ionic and nonionic contrast media in 1196 patients: a randomized trial. The iohexol cooperative study. Kidney Int. 1995;47(1):254–261.
   PubMed Web of Science ®Google Scholar
• Mehran R, Dangas GD, Weisbord SD. Contrast-Associated acute kidney injury. N Engl J Med. 2019;380(22):2146–2155.
   PubMed Web of Science ®Google Scholar
• ACT Investigators. Acetylcysteine for prevention of renal outcomes in patients undergoing coronary and peripheral vascular angiography: main results from the randomized acetylcysteine for contrast-induced nephropathy trial (ACT). Circulation. 2011;124(11):1250–1259.
   PubMed Web of Science ®Google Scholar
• Awal A, Ahsan SA, Siddique MA, et al. Effect of hydration with or without n-acetylcysteine on contrast-induced nephropathy in patients undergoing coronary angiography and percutaneous coronary intervention. Mymensingh Med J. 2011;20(2):264–269.
   PubMedGoogle Scholar
• Albabtain MA, Almasood A, Alshurafah H, et al. Efficacy of ascorbic acid, n-acetylcysteine, or combination of both on top of saline hydration versus saline hydration alone on prevention of contrast-induced nephropathy: a prospective randomized study. J Interv Cardiol. 2013;26(1):90–96.
   PubMed Web of Science ®Google Scholar
• Erol T, Tekin A, Katırcıbaşı MT, et al. Efficacy of allopurinol pretreatment for prevention of contrast-induced nephropathy: a randomized controlled trial. Int J Cardiol. 2013;167(4):1396–1399.
   PubMed Web of Science ®Google Scholar
• Kumar A, Bhawani G, Kumari N, et al. Comparative study of renal protective effects of allopurinol and N-acetyl-cysteine on contrast-induced nephropathy in patients undergoing cardiac catheterization. J Clin Diagn Res. 2014;8(12):HC03–HC7.
   PubMedGoogle Scholar
• Sánchez-Lozada LG, Lanaspa MA, Cristóbal-García M, et al. Uric acid-induced endothelial dysfunction is associated with mitochondrial alterations and decreased intracellular ATP concentrations. Nephron Exp Nephrol. 2012;121(3-4):e71–e78.
   PubMedGoogle Scholar
• Cristóbal-García M, García-Arroyo FE, Tapia E, et al. Renal oxidative stress induced by long-term hyperuricemia alters mitochondrial function and maintains systemic hypertension. Oxid Med Cell Longev. 2015;2015:1–8.
   Web of Science ®Google Scholar
• Haerteis S, Krappitz M, Diakov A, et al. Plasmin and chymotrypsin have distinct preferences for channel activating cleavage sites in the γ subunit of the human epithelial sodium channel. J Gen Physiol. 2012;140(4):375–389.
   PubMed Web of Science ®Google Scholar
• Glorie LL, Verhulst A, Matheeussen V, et al. DPP4 inhibition improves functional outcome after renal ischemia-reperfusion injury. Am J Physiol Renal Physiol. 2012;303(5):F681–F688.
   PubMed Web of Science ®Google Scholar
• Reichetzeder C, von Websky K, Tsuprykov O, et al. Head-to-head comparison of structurally unrelated dipeptidyl peptidase 4 inhibitors in the setting of renal ischemia-reperfusion injury. Br J Pharmacol. 2017;174(14):2273–2286.
   PubMed Web of Science ®Google Scholar
• Rachoin JS, Wolfe Y, Patel S, et al. Contrast associated nephropathy after intravenous administration: what is the magnitude of the problem? Ren Fail. 2021;43(1):1311–1321.
   PubMed Web of Science ®Google Scholar